In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Extensively drug-resistant (XDR) Acinetobacter spp. are a growing threat in healthcare settings, particularly intensive care units.
• Increasing resistance to colistin necessitates the development of alternative therapeutic strategies.
• Novel antibiotic combinations are being explored to combat XDR Acinetobacter baumannii.

Purpose of the Study:

• To evaluate the in vitro efficacy of novel antibiotic combinations against XDR Acinetobacter baumannii using a pharmacokinetics-pharmacodynamics (PK/PD) model.
• To compare the effectiveness of single-agent antibiotic regimens with combination therapies.
• To identify potential alternative treatments for XDR Acinetobacter baumannii infections.

Main Methods:

• Three clinical strains of XDR Acinetobacter baumannii were tested.
• Simulated antibiotic regimens included colistin, daptomycin, imipenem, and ertapenem, both as single agents and in combinations (colistin-daptomycin, colistin-imipenem, imipenem-ertapenem).
• Bacterial viability (log10 CFU/ml) was assessed at multiple time points (0, 1, 2, 4, 8, 24 hours) in an in vitro PK/PD model.

Main Results:

• Colistin monotherapy showed significant bacterial reduction but did not reach the limit of detection, with one strain exhibiting regrowth.
• The daptomycin-colistin combination demonstrated superior efficacy compared to colistin alone, achieving the limit of detection at 24 hours for all strains.
• Imipenem-ertapenem combination outperformed colistin but did not reach the limit of detection, while colistin-imipenem showed initial reduction but led to colistin resistance and regrowth.

Conclusions:

• The daptomycin-colistin combination emerged as the most effective regimen against XDR Acinetobacter baumannii in this in vitro study.
• Novel antibiotic combinations, particularly daptomycin-colistin, represent promising alternatives for treating challenging XDR Acinetobacter baumannii infections.
• Further investigation of the daptomycin-colistin combination in future studies is warranted.